Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $108,900.00 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the completion of the transaction, the insider owned 117,227 shares in the company, valued at $2,930,675. The trade was a 3.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total transaction of $89,942.86.
• On Thursday, June 25th, Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00.

Nurix Therapeutics Stock Performance

NRIX opened at $25.53 on Friday. The stock has a market capitalization of $2.65 billion, a PE ratio of -7.40 and a beta of 1.79. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $25.89. The business’s 50 day moving average price is $21.26 and its 200 day moving average price is $18.06.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The business had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NRIX has been the topic of several recent analyst reports. Morgan Stanley upped their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Oppenheimer began coverage on Nurix Therapeutics in a research note on Monday, June 29th. They set an “outperform” rating and a $28.00 price target on the stock. UBS Group raised their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Finally, Jefferies Financial Group lifted their price objective on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Nurix Therapeutics in the second quarter worth $212,769,000. Deutsche Bank AG acquired a new position in Nurix Therapeutics during the 2nd quarter worth $3,674,000. Persistent Asset Partners Ltd purchased a new stake in Nurix Therapeutics during the 2nd quarter worth about $751,000. Global Retirement Partners LLC purchased a new stake in Nurix Therapeutics during the 2nd quarter worth about $82,000. Finally, Bank of New York Mellon Corp acquired a new stake in Nurix Therapeutics in the 2nd quarter valued at about $6,614,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.